Accessibility StatementSkip Navigation WHAT'S NEXT? If you suffered a loss in MoonLake during the relevant time frame, you have until December 15, 2025Â to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the pas ...

Core Viewpoint - MoonLake Immunotherapeutics has been sued for securities fraud, with allegations that the company misrepresented its clinical data and the efficacy of its investigational drug sonelokimab [1][3][4]. Group 1: Lawsuit Details - A lawsuit has been filed against MoonLake and certain senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][3]. - Investors have until December 15, 2025, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Southern District of New York [3]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its Phase 3 VELA trials for sonelokimab [4]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated a superior clinical response for patients compared to competitors [5]. Group 3: Allegations and Impact - The lawsuit alleges that the clinical data and Nanobody structure of sonelokimab did not provide a superior clinical benefit over competitors, raising doubts about the drug's regulatory approval and commercial viability [6]. - Following the announcement of disappointing results from the VELA Phase 3 trials, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [7].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - November 13 ...

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, an investigational therapeutic aimed at treating moderate to severe hidradenitis suppurativa [3]. Clinical Data and Claims - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses for patients and a competitive edge for sonelokimab [4]. - The company asserted that the Nanobody structure of SLK provided beneficial differences compared to traditional monoclonal antibody treatments [4]. Allegations and Stock Impact - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit over competitors, raising doubts about the drug's regulatory approval and commercial viability [5]. - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock plummeted nearly 90%, from $61.99 to $6.24 per share [6].

New York, New York--(Newsfile Corp. - November 12, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=177026&wire=5&utm_campaign=14or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.Can ...

ROSEN, LEADING TRIAL ATTORNEYS, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 12, 2025 4:21 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 12, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Per ...

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, with a deadline for investors to seek recovery by December 15, 2025 [2][4]. Group 1: Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [5]. - The company conducted Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa (HS) [5]. Group 2: Allegations and Clinical Data - The lawsuit alleges that MoonLake misrepresented its clinical data, claiming that its "strong clinical data" would lead to superior clinical responses compared to competitors [6]. - It is claimed that the Nanobody structure of SLK did not provide a clinical benefit over traditional monoclonal antibody treatments, raising doubts about the drug's regulatory approval and commercial viability [7]. Group 3: Stock Performance and Impact - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake Immunotherapeutics due to allegations of false and misleading statements regarding its product SLK, which failed to demonstrate competitive efficacy compared to BIMZELX, leading to significant stock price decline [2][5][6][7]. Group 1: Legal Action and Deadlines - A federal securities class action has been filed against MoonLake, with a lead plaintiff deadline set for December 15, 2025 [2][8]. - Investors who suffered losses between March 10, 2024, and September 29, 2025, are encouraged to discuss their legal rights with Faruqi & Faruqi [1][2]. Group 2: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives violated federal securities laws by making false statements and failing to disclose critical information about the differences between Nanobodies and monoclonal antibodies [5]. - Specific allegations include claims that SLK's structure would not provide superior clinical benefits over BIMZELX and that its supposed increased tissue penetration would not lead to improved clinical efficacy [5]. Group 3: Stock Performance Impact - Following the announcement of disappointing Phase 3 VELA program results, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [6][7].

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a class action lawsuit related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by December 15, 2025, to represent other class members [4][6]. Group 2: Legal Representation - Investors are advised to choose qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [5]. - The Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in terms of settlements achieved [5]. Group 3: Allegations Against MoonLake - The complaint alleges that during the class period, MoonLake made false or misleading statements regarding its product SLK, particularly in comparison to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [6].

Core Viewpoint - The MoonLake class action lawsuit alleges that MoonLake Immunotherapeutics and certain executives violated the Securities Exchange Act of 1934, impacting investors who purchased or acquired its common stock [1][3]. Group 1: Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases, with its sole drug candidate being sonelokimab (SLK) aimed at treating hidradenitis suppurativa (HS) [3][4]. - The commercial prospects of SLK were contingent on demonstrating efficacy comparable or superior to Union Chimique Belge's BIMZELX, an FDA-approved monoclonal antibody for HS [3]. Group 2: Allegations and Impact - The lawsuit claims that during the class period, MoonLake made false or misleading statements regarding SLK's clinical benefits, including its molecular targets and tissue penetration capabilities [4]. - On September 28, 2025, MoonLake announced that SLK failed to show competitive efficacy compared to BIMZELX in its Phase 3 VELA program, leading to a nearly 90% drop in the stock price [5].